RNA transfection

DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Retrieved on: 
Monday, January 17, 2022 - 12:04pm

Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.

Key Points: 
  • Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.
  • "Mariola's dedication and expertise helped to build CureVac and fundamentally contributed to the advancement of mRNA technology as a whole."
  • "Mariola's groundbreaking work and innovations in mRNA technology have strongly contributed to CureVac becoming the world's pioneering company to harness mRNA for medical purposes," added Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Mariola Fotin-Mleczek joined CureVac in May 2006 and became a member of the management board in 2013, first as Chief Scientific Officer and as Chief Technology Officer in 2018.

ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination

Retrieved on: 
Friday, January 14, 2022 - 3:30pm

The Special Meeting to approve the proposed business combination and related matters is scheduled to be held on February 1st, 2022 at 9:00 A.M. Eastern time.

Key Points: 
  • The Special Meeting to approve the proposed business combination and related matters is scheduled to be held on February 1st, 2022 at 9:00 A.M. Eastern time.
  • The Special Meeting will be conducted completely virtually, and can be accessed via live webcast at www.virtualshareholdermeeting.com/ENVI2022SM .
  • For more information, visit https://www.greenlightbiosciences.com/
    In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).
  • Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. ("GreenLight") and Environmental Impact Acquisition Corp. ("ENVI").

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am

These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am

WARSAW, Poland, Jan. 14, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces the appointment of Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński to its Supervisory Board. These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation

Retrieved on: 
Thursday, January 13, 2022 - 1:00pm

That is why "drug delivery technologies" are said to be the choke point of drug and gene therapies.

Key Points: 
  • That is why "drug delivery technologies" are said to be the choke point of drug and gene therapies.
  • The drug delivery technologies of N1 Life have demonstrated significant advantages in non-antigen-dependent tumor targeting, tumor tissue and cell penetration, and overcoming multi-drug resistance.
  • "We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development.
  • It is committed to applying innovative drug delivery technologies to the development of clinical products that address unmet medical needs.

 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Retrieved on: 
Thursday, January 13, 2022 - 1:03pm

By restoring immune balance through selective modulation of NRP2, efzofitimod is the first tRNA synthetase-derived and NRP2-targeting therapy to demonstrate clinical activity in patients.

Key Points: 
  • By restoring immune balance through selective modulation of NRP2, efzofitimod is the first tRNA synthetase-derived and NRP2-targeting therapy to demonstrate clinical activity in patients.
  • We look forward to initiating a registrational trial of efzofitimod in our lead indication, pulmonary sarcoidosis, this year.
  • The USAN Council and WHO are responsible for selecting simple, informative and unique nonproprietary (generic) drug names.
  • aTyr is developing efzofitimod as a potential therapeutic for patients with severe inflammatory lung diseases.

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

EMERYVILLE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the first patient has been enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.

Key Points: 
  • The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC).
  • We expect to report initial Phase 2 data from the GRANITE-CRC-1L trial in mid-2023.
  • Additionally, the company reported updated overall survival (OS) data from its Phase 1/2 GRANITE trial evaluating individualized immunotherapy in combination with nivolumab (OPDIVO) and ipilimumab (YERVOY) in patients with advanced solid tumors, specifically end-stage metastatic MSS-CRC.
  • GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS-CRC.

ARTRYA APPOINTS RENOWNED EXECUTIVE DR JACQUE SOKOLOV AS UNITED STATES ADVISOR

Retrieved on: 
Thursday, January 13, 2022 - 11:00am

Artrya Managing Director and Co-founder, John Barrington AM, commented: "I am delighted to welcome Jacque Sokolov to the Company.

Key Points: 
  • Artrya Managing Director and Co-founder, John Barrington AM, commented: "I am delighted to welcome Jacque Sokolov to the Company.
  • Dr Sokolov brings a remarkable breadth of experience across all aspects of the US healthcare industry, in particular healthcare delivery and biotechnology, and is formally trained as an academic cardiologist."
  • "Dr Sokolov will support our US clinical research by helping to form key partnerships with research institutes and study sites.
  • Dr. Sokolov is chairman and chief executive officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company.

FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development

Retrieved on: 
Thursday, January 13, 2022 - 7:00am

With industry capacity restrictions and throughput bottlenecks, gene therapy manufacturers wait, on average, ten months for production, analytical analysis, and release of plasmids.

Key Points: 
  • With industry capacity restrictions and throughput bottlenecks, gene therapy manufacturers wait, on average, ten months for production, analytical analysis, and release of plasmids.
  • This wait, combined with delays associated with fragmented materials suppliers and CDMOs, often results in a gene therapy commercial manufacturing timeline of approximately 18 months.
  • While the GMP plasmid DNA offering is key to vertically integrating the complete gene therapy manufacturing process for Andelyn's clients, increased production capacity is another factor.
  • Capacity expansions coupled with our clinical-grade plasmid DNA offering allows us to be a fully vertically integrated gene therapy CDMO continuing to contribute to the capacity and capabilities required to advance the gene therapy sector."

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

Retrieved on: 
Thursday, January 13, 2022 - 12:52am

INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually from January 10th to 13th with leaders from major pharmaceutical and biopharmaceutical companies and key investors.

Key Points: 
  • INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually from January 10th to 13th with leaders from major pharmaceutical and biopharmaceutical companies and key investors.
  • "For Samsung Biologics, 2022 will be a year where we will be able to take a great leap forward for sustainable growth and endeavor to maximize our capabilities as a leading CDMO," said John Rim, CEO of Samsung Biologics during his presentation at the conference.
  • "The strategic roadmap and milestones outlined today illustrate the key success drivers for our growth this year as well as lay a strong groundwork for sustainable growth opportunities ahead of us," Rim added.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.